| Name | Title | Contact Details |
|---|
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
Kira Pharmaceuticals is pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases
AC Immune SA, a global leader in developing precision medicine for neurodegenerative diseases (incl. Alzheimer & Parkinsons) with cutting-edge technology platforms
Thomson Research Associates is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.